<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diagnostic approach to the adult with jaundice or asymptomatic hyperbilirubinemia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diagnostic approach to the adult with jaundice or asymptomatic hyperbilirubinemia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Diagnostic approach to the adult with jaundice or asymptomatic hyperbilirubinemia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Namita Roy-Chowdhury, PhD, FAASLD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jayanta Roy-Chowdhury, MD, MRCP, AGAF, FAASLD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sanjiv Chopra, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 12, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Jaundice and asymptomatic hyperbilirubinemia are common clinical problems that can be caused by a variety of disorders, including bilirubin overproduction, impaired bilirubin conjugation, biliary obstruction, and hepatic inflammation. (See  <a class="medical medical_review" href="/d/html/3615.html" rel="external">"Classification and causes of jaundice or asymptomatic hyperbilirubinemia"</a>.)</p><p>This topic will provide an overview of the diagnostic approach to adults with jaundice or asymptomatic hyperbilirubinemia. The causes of jaundice and asymptomatic hyperbilirubinemia, detailed discussions of the specific testing used, and the evaluation of patients with other liver test abnormalities are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/3615.html" rel="external">"Classification and causes of jaundice or asymptomatic hyperbilirubinemia"</a> and  <a class="medical medical_review" href="/d/html/3576.html" rel="external">"Approach to the patient with abnormal liver biochemical and function tests"</a>.)</p><p class="headingAnchor" id="H58686867"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>For clinical purposes, serum bilirubin is fractionated to classify hyperbilirubinemia into one of two major categories  (<a class="graphic graphic_table graphicRef55607" href="/d/graphic/55607.html" rel="external">table 1</a>) (see  <a class="medical medical_review" href="/d/html/3615.html" rel="external">"Classification and causes of jaundice or asymptomatic hyperbilirubinemia"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unconjugated hyperbilirubinemia</strong> – Unconjugated hyperbilirubinemia is characterized by plasma elevation of predominantly unconjugated (indirect) bilirubin. This may be due to the overproduction of bilirubin, impaired bilirubin uptake by the liver, or abnormalities of bilirubin conjugation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Conjugated hyperbilirubinemia</strong> – In patients with conjugated hyperbilirubinemia, <strong>both</strong> unconjugated and conjugated (direct) bilirubin are elevated. This may be due to hepatocellular disease, impaired canalicular excretion of bilirubin, or biliary obstruction. </p><p></p><p class="headingAnchor" id="H58686958"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>The diagnostic approach to the jaundiced patient begins with a careful history, physical examination, and initial laboratory studies [<a href="#rid1">1</a>]. A differential diagnosis is formulated based on those results and additional testing is performed to narrow the diagnostic possibilities.</p><p>Although the evaluation is usually not urgent, jaundice can reflect a medical emergency in a few situations. These include massive hemolysis (eg, due to <em>Clostridium perfringens</em> sepsis or falciparum malaria), ascending cholangitis, and fulminant hepatic failure. However, patients with these conditions are not asymptomatic. Expedient diagnosis and appropriate therapy can be life-saving in these settings.</p><p class="headingAnchor" id="H2"><span class="h2">History</span><span class="headingEndMark"> — </span>Multiple clues to the etiology of a patient's hyperbilirubinemia can be obtained from the history information and should include the following (see  <a class="medical medical_review" href="/d/html/3576.html" rel="external">"Approach to the patient with abnormal liver biochemical and function tests", section on 'History'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Use of medications, herbal medications, dietary supplements, and recreational drugs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Significant alcohol consumption (&gt;210 grams of alcohol (15 drinks) per week in males, &gt;140 grams of alcohol (10 drinks) per week in females.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hepatitis risk factors (eg, travel to endemic areas, blood transfusions prior to 1992, intravenous drug use). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>History of abdominal operations, including gallbladder surgery.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>History of inherited disorders, including liver diseases and hemolytic disorders.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HIV status.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Occupational or recreational exposure to toxic substances. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Associated symptoms that should be elicited include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Development/worsening of jaundice during times of stress is suggestive of Gilbert syndrome. (See  <a class="medical medical_review" href="/d/html/3578.html" rel="external">"Gilbert syndrome"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fever, particularly when associated with chills or right upper quadrant pain and/or a history of prior biliary surgery, is suggestive of acute cholangitis. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Anorexia, malaise, and myalgias may suggest viral hepatitis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Right upper quadrant pain suggests extrahepatic biliary obstruction. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acholic stool (also termed clay-colored stool) refers to stool without the yellow-brown color, which is normally derived mainly from the bilirubin breakdown products, urobilin and stercobilin. Although rare, it can also be seen in the acute cholestatic phase of viral hepatitis and in prolonged near-complete common bile duct obstruction from cancer of the pancreatic head or the duodenal ampulla.</p><p></p><p class="headingAnchor" id="H1589110226"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>The physical examination may reveal a Courvoisier sign (a palpable gallbladder, caused by obstruction distal to the takeoff of the cystic duct by malignancy) or signs of chronic liver failure/portal hypertension such as ascites, splenomegaly, spider angiomata, and gynecomastia. Certain findings suggest specific diseases, such as hyperpigmentation in hemochromatosis, Kayser-Fleischer rings in Wilson disease, and xanthomas in primary biliary cholangitis [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/d/html/3576.html" rel="external">"Approach to the patient with abnormal liver biochemical and function tests", section on 'Physical examination'</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Initial laboratory tests and interpretation</span><span class="headingEndMark"> — </span>Initial laboratory tests include measurements of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Serum total and unconjugated bilirubin</p><p class="bulletIndent1"><span class="glyph">●</span>Alkaline phosphatase</p><p class="bulletIndent1"><span class="glyph">●</span>Aminotransferases (aspartate aminotransferase [AST] and alanine aminotransferase [ALT])</p><p class="bulletIndent1"><span class="glyph">●</span>Prothrombin time/international normalized ratio (INR)</p><p class="bulletIndent1"><span class="glyph">●</span>Albumin </p><p></p><p><strong>Assessment of patterns of elevation</strong> — Subsequent testing is guided by the predominant pattern of liver injury. Major patterns of injury and their characteristics include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cholestatic injury pattern  </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Disproportionate elevation in the alkaline phosphatase compared with the serum aminotransferases (eg, R value* ≤2)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Serum bilirubin may be elevated</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tests of synthetic function (eg, albumin, prothrombin time) may be abnormal</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hepatocellular injury pattern  </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Disproportionate elevation (relative to the upper limit of normal [ULN]) in the serum aminotransferases (ALT and AST) compared with the alkaline phosphatase (eg, R value* ≥5)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Serum bilirubin may be elevated</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tests of synthetic function (eg, albumin, prothrombin time) may be abnormal</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Isolated hyperbilirubinemia </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Elevated bilirubin level (total or direct) with normal serum aminotransferases and alkaline phosphatase</p><p></p><p>However, while liver tests provide a broad guideline for the initial distinction between the different causes of jaundice, exceptions do occur. As an example, viral hepatitis, which normally presents primarily with an elevation of serum aminotransferases, may present as a predominantly cholestatic syndrome with marked pruritus. </p><p>In patients with conjugated hyperbilirubinemia, the evaluation will be based on whether the abnormalities are likely due to biliary obstruction, intrahepatic cholestasis, hepatocellular injury, or an inherited condition (based on the presence of isolated conjugated hyperbilirubinemia).</p><p class="headingAnchor" id="H4"><span class="h2">Subsequent testing based on pattern of liver injury</span><span class="headingEndMark"> — </span>Subsequent studies are guided based on findings from the history, physical examination, and initial laboratory tests. (See <a class="local">'Initial laboratory tests and interpretation'</a> above.)</p><p class="headingAnchor" id="H2263100072"><span class="h3">Patients with hyperbilirubinemia and a cholestatic injury pattern</span><span class="headingEndMark"> — </span>Elevation of the serum alkaline phosphatase out of proportion to the serum aminotransferases suggests biliary obstruction or intrahepatic cholestasis  (<a class="graphic graphic_algorithm graphicRef141797" data-inline-graphics="141797" href="/d/graphic/141797.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/d/html/3576.html" rel="external">"Approach to the patient with abnormal liver biochemical and function tests", section on 'Elevated alkaline phosphatase'</a>.)</p><p class="headingAnchor" id="H2352292443"><span class="h4">Hepatic imaging for extrahepatic cholestasis</span><span class="headingEndMark"> — </span>Testing in patients with elevated bilirubin and alkaline phosphatase of hepatic origin typically starts with right upper quadrant ultrasonography to assess the hepatic parenchyma and bile ducts [<a href="#rid3">3</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>The presence of biliary ductal dilatation on imaging suggests extrahepatic cholestasis. If ultrasonography shows biliary ductal dilatation without an apparent cause, advanced imaging with either magnetic resonance cholangiopancreatography (MRCP) or endoscopic ultrasound (EUS) is obtained to confirm biliary ductal dilatation and determine the etiology. Endoscopic retrograde cholangiopancreatography (ERCP) is reserved for therapy to remove stones or stenting a stricture. (See  <a class="medical medical_review" href="/d/html/13922.html" rel="external">"Choledocholithiasis: Clinical manifestations, diagnosis, and management", section on 'Additional imaging (MRCP or EUS)'</a> and  <a class="medical medical_review" href="/d/html/632.html" rel="external">"Overview of endoscopic retrograde cholangiopancreatography (ERCP) in adults"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The absence of biliary ductal dilatation suggests intrahepatic cholestasis. (See <a class="local">'Evaluation for intrahepatic cholestasis'</a> below.)</p><p></p><p class="headingAnchor" id="H805282284"><span class="h4">Evaluation for intrahepatic cholestasis</span><span class="headingEndMark"> — </span>In many cases, a possible cause of intrahepatic cholestasis can be identified based on the patient's history. If a likely source is identified, additional testing may not be required. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Discontinue culprit medications</strong> – Any medications or supplements associated with cholestasis should be discontinued. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory tests</strong> – There are numerous possible causes of intrahepatic cholestasis, including primary biliary cholangitis, primary sclerosing cholangitis, viral hepatitis, intrahepatic cholestasis of pregnancy, benign postoperative cholestasis, and infiltrative disease. The testing should be informed by the patient's history and risk factors. Typically, the evaluation starts with testing for primary biliary cholangitis along with any other conditions for which the patient is at increased risk due to history or possible exposure (eg, testing for primary sclerosing cholangitis in a patient with ulcerative colitis, obtaining serum bile acids in a woman who is pregnant).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Primary biliary cholangitis: Antimitochondrial antibody</p><p class="bulletIndent2"><span class="glyph">•</span>Primary sclerosing cholangitis: MRCP</p><p class="bulletIndent2"><span class="glyph">•</span>Hepatitis A virus: Immunoglobulin M (IgM) antihepatitis A</p><p class="bulletIndent2"><span class="glyph">•</span>Hepatitis B virus: Hepatitis B surface antigen, IgM antihepatitis core antigen, antibody to hepatitis B surface antigen</p><p class="bulletIndent2"><span class="glyph">•</span>Hepatitis C virus: Antihepatitis C antibody, hepatitis C viral RNA</p><p class="bulletIndent2"><span class="glyph">•</span>Hepatitis E virus: Hepatitis E virus antibodies</p><p class="bulletIndent2"><span class="glyph">•</span>Cytomegalovirus (CMV): Anti-CMV antibodies, CMV antigen</p><p class="bulletIndent2"><span class="glyph">•</span>Epstein-Barr virus: Heterophile antibody</p><p class="bulletIndent2"><span class="glyph">•</span>Intrahepatic cholestasis of pregnancy: Serum pregnancy test, serum bile acids</p><p></p><p>Patients with unexplained cholestasis despite serologic evaluation and imaging, should be referred to a hepatologist for further evaluation and consideration of a liver biopsy to rule out infiltrative disease.</p><p class="headingAnchor" id="H2987419943"><span class="h3">Patients with isolated hyperbilirubinemia</span><span class="headingEndMark"> — </span>If the alkaline phosphatase and aminotransferases are normal, hyperbilirubinemia is likely not due to hepatic injury or biliary tract disease. Further evaluation is based on the type of hyperbilirubinemia [<a href="#rid4">4</a>]. (See <a class="local">'Terminology'</a> above.)</p><p class="headingAnchor" id="H2510784518"><span class="h4">Isolated unconjugated hyperbilirubinemia</span><span class="headingEndMark"> — </span>The initial evaluation of a patient with isolated unconjugated hyperbilirubinemia includes an assessment for hemolytic anemia and discontinuation of medications (eg, <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> and <a class="drug drug_general" data-topicid="9812" href="/d/drug information/9812.html" rel="external">probenecid</a>) that impair hepatic uptake of bilirubin  (<a class="graphic graphic_algorithm graphicRef141804" data-inline-graphics="141804" href="/d/graphic/141804.html" rel="external">algorithm 2</a>). In a patient with a history consistent with Gilbert syndrome (persistent unconjugated hyperbilirubinemia &lt;4 mg/dL, no evidence of hemolysis and normal plasma aminotransferases and alkaline phosphatase concentrations with development of jaundice during times of stress), additional testing is not required. However, patients with unconjugated bilirubin levels ≥4 mg/dL or abnormal aminotransferases should be referred to a hepatologist for further evaluation and consideration of a liver biopsy. (See  <a class="medical medical_review" href="/d/html/7076.html" rel="external">"Diagnosis of hemolytic anemia in adults"</a> and  <a class="medical medical_review" href="/d/html/3578.html" rel="external">"Gilbert syndrome"</a> and  <a class="medical medical_review" href="/d/html/3569.html" rel="external">"Crigler-Najjar syndrome"</a>.)</p><p class="headingAnchor" id="H1540086163"><span class="h4">Isolated conjugated hyperbilirubinemia</span><span class="headingEndMark"> — </span>Conjugated hyperbilirubinemia without other routine liver test abnormalities is found in two rare inherited conditions: Dubin-Johnson syndrome and Rotor syndrome. Dubin-Johnson syndrome and Rotor syndrome should be suspected in patients with mild hyperbilirubinemia (with a conjugated fraction of approximately 50 percent) in the absence of other abnormalities of standard liver biochemical tests. Differentiating between these syndromes is possible but clinically unnecessary due to their benign nature. (See  <a class="medical medical_review" href="/d/html/3584.html" rel="external">"Inherited disorders associated with conjugated hyperbilirubinemia"</a>.)</p><p class="headingAnchor" id="H2356526912"><span class="h3">Patients with hyperbilirubinemia and a hepatocellular injury pattern</span><span class="headingEndMark"> — </span>A predominant elevation of serum aminotransferase activity suggests that jaundice is caused by intrinsic hepatocellular disease  (<a class="graphic graphic_table graphicRef66083" href="/d/graphic/66083.html" rel="external">table 2</a>). The evaluation is based on the degree and pattern of aminotransferase elevation and is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/3576.html" rel="external">"Approach to the patient with abnormal liver biochemical and function tests", section on 'Laboratory tests'</a>.)</p><p class="headingAnchor" id="H3054482799"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112064.html" rel="external">"Society guideline links: Abnormal liver biochemical tests"</a>.)</p><p class="headingAnchor" id="H22361357"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/16983.html" rel="external">"Patient education: Jaundice in adults (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H12"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification of hyperbilirubinemia</strong> – For clinical purposes, serum bilirubin is fractionated to classify hyperbilirubinemia into one of two major categories: unconjugated (indirect) hyperbilirubinemia and conjugated (direct) hyperbilirubinemia. Unconjugated hyperbilirubinemia is characterized by plasma elevation of predominantly unconjugated (indirect) bilirubin. This may be due to the overproduction of bilirubin, impaired bilirubin uptake by the liver, or abnormalities of bilirubin conjugation. In patients with conjugated hyperbilirubinemia, <strong>both</strong> unconjugated and conjugated (direct) bilirubin are elevated. This may be due to hepatocellular disease, impaired canalicular excretion of bilirubin, or biliary obstruction. (See <a class="local">'Terminology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Historical clues</strong> – Multiple clues to the etiology of hyperbilirubinemia can be obtained from the history (see <a class="local">'History'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Use of medications, herbal medications, dietary supplements, and recreational drugs</p><p class="bulletIndent2"><span class="glyph">•</span>Significant alcohol consumption (&gt;210 grams of alcohol (15 drinks) per week in males, &gt;140 grams of alcohol (10 drinks) per week in females</p><p class="bulletIndent2"><span class="glyph">•</span>Hepatitis risk factors (eg, travel to endemic areas, blood transfusions prior to 1992, intravenous drug use) </p><p class="bulletIndent2"><span class="glyph">•</span>History of abdominal operations, including gallbladder surgery</p><p class="bulletIndent2"><span class="glyph">•</span>History of inherited disorders, including liver diseases and hemolytic disorders</p><p class="bulletIndent2"><span class="glyph">•</span>HIV status</p><p class="bulletIndent2"><span class="glyph">•</span>Occupational or recreational exposure to toxic substances </p><p class="bulletIndent2"><span class="glyph">•</span>Associated symptoms (eg, fever, right upper quadrant pain, myalgias)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory evaluation </strong>– Initial laboratory tests include measurements of serum total and unconjugated bilirubin, alkaline phosphatase, aminotransferases (aspartate aminotransferase and alanine aminotransferase), prothrombin time/international normalized ratio, and albumin. Subsequent testing is guided by the predominant pattern of liver injury. (See <a class="local">'Initial laboratory tests and interpretation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional testing to determine etiology of hyperbilirubinemia based on pattern of liver tests</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Conjugated hyperbilirubinemia and elevated alkaline phosphatase</strong> – Elevation of the serum alkaline phosphatase out of proportion to the serum aminotransferases suggests biliary obstruction or intrahepatic cholestasis. Testing in patients with elevated bilirubin and alkaline phosphatase of hepatic origin typically starts with right upper quadrant ultrasonography to assess the hepatic parenchyma and bile ducts  (<a class="graphic graphic_algorithm graphicRef141797" href="/d/graphic/141797.html" rel="external">algorithm 1</a>). The absence of biliary ductal dilatation suggests intrahepatic cholestasis. (See <a class="local">'Patients with hyperbilirubinemia and a cholestatic injury pattern'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Conjugated hyperbilirubinemia and hepatocellular injury</strong> – A predominant elevation of serum aminotransferase activity suggests that jaundice is caused by intrinsic hepatocellular disease  (<a class="graphic graphic_table graphicRef66083" href="/d/graphic/66083.html" rel="external">table 2</a>). The evaluation is based on the degree and pattern of aminotransferase elevation and is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/3576.html" rel="external">"Approach to the patient with abnormal liver biochemical and function tests", section on 'Elevated serum aminotransferases'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Isolated unconjugated hyperbilirubinemia</strong> – The evaluation of unconjugated hyperbilirubinemia typically involves evaluation for hemolytic anemia, drugs that impair hepatic uptake of bilirubin, and Gilbert syndrome  (<a class="graphic graphic_algorithm graphicRef141804" href="/d/graphic/141804.html" rel="external">algorithm 2</a>). However, patients with unconjugated bilirubin levels ≥4 mg/dL or abnormal aminotransferases should be referred to a hepatologist for further evaluation and consideration of a liver biopsy. (See <a class="local">'Isolated unconjugated hyperbilirubinemia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Isolated conjugated hyperbilirubinemia</strong> – Conjugated hyperbilirubinemia without other routine liver test abnormalities is found in two rare inherited conditions: Dubin-Johnson syndrome and Rotor syndrome. Normal levels of serum alkaline phosphatase and gamma-glutamyl transpeptidase help distinguish these conditions from disorders associated with biliary obstruction. (See <a class="local">'Isolated conjugated hyperbilirubinemia'</a> above.)</p><p></p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol 2017; 112:18.</a></li><li><a class="nounderline abstract_t">Roberts EA, Schilsky ML. Current and Emerging Issues in Wilson's Disease. N Engl J Med 2023; 389:922.</a></li><li><a class="nounderline abstract_t">Saini S. Imaging of the hepatobiliary tract. N Engl J Med 1997; 336:1889.</a></li><li><a class="nounderline abstract_t">Newsome PN, Cramb R, Davison SM, et al. Guidelines on the management of abnormal liver blood tests. Gut 2018; 67:6.</a></li></ol></div><div id="topicVersionRevision">Topic 3620 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27995906" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37672695" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Current and Emerging Issues in Wilson's Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9197218" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Imaging of the hepatobiliary tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29122851" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Guidelines on the management of abnormal liver blood tests.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
